Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
Trovan Preservative Free is an injectable fluoroquinolone antibiotic (alatrofloxacin mesylate) approved in 1997 for treating serious bacterial infections. As a broad-spectrum fluoroquinolone, it targets gram-positive and gram-negative organisms and is administered intravenously. The preservative-free formulation was designed to minimize irritation and improve tolerability in vulnerable patient populations.
With LOE approaching on a legacy injectable antibiotic, commercial teams are likely small and focused on managed care retention and hospital formulary maintenance rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Trovan at this lifecycle stage offers limited career upside; roles are primarily defensive and focused on slowing market share loss rather than growth. Professionals joining this product should expect modest team size, managed care negotiation focus, and limited advancement into larger franchise roles.
Worked on TROVAN PRESERVATIVE FREE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.